Common Contracts
3 similar Development and License Agreement contracts by Emisphere Technologies Inc
Development and licensing agreement for oral formulation of insulinDevelopment and License Agreement • January 31st, 2022 • New York
Emisphere and Novo Nordisk entered an exclusive Development and License Agreement to develop and commercialize oral formulations of Novo Nordisk's insulins using Emisphere's Eligen® Technology.
Development and License Agreement (Insulin)Development and License Agreement • December 21st, 2010 • Emisphere Technologies Inc • Pharmaceutical preparations • New York
THIS DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”) is entered into as of 20 December, 2010 (the “Effective Date”) by and between and EMISPHERE TECHNOLOGIES, INC., a Delaware corporation having an address at 240 Cedar Knolls Road, Cedar Knolls, NJ 07927, USA (“Emisphere”) and NOVO NORDISK AS, a Danish corporation having an address at Novo Allé, 2880 Bagsvaerd, Denmark (“Novo Nordisk”).
Development and License AgreementDevelopment and License Agreement • August 11th, 2008 • Emisphere Technologies Inc • Pharmaceutical preparations • New York
THIS DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”) is entered into as of 21 June, 2008 (the “Effective Date”) by and between and EMISPHERE TECHNOLOGIES, INC., a Delaware corporation having an address at 240 Cedar Knolls Road, Cedar Knolls, NJ 07927, USA (“Emisphere”) and NOVO NORDISK AS, a Danish corporation having an address at Novo Allé, 2880 Bagsvaerd, Denmark (“Novo Nordisk”).
